How long can you live with stage three multiple myeloma?

Multiple myeloma is a malignant tumor originating from bone marrow plasma cells. It interferes with normal hematopoietic function and affects bones and other tissues and organs. When the disease progresses to stage three, it means that the condition has become quite serious and myeloma cells have spread widely in the body. Life expectancy for stage III patients is affected by a variety of factors, including overall health, response to treatment, and severity of complications.

In the third stage, due to the widespread spread of myeloma cells, multiple organs and tissues of the body may be damaged, leading to a series of complications, such as anemia, hypercalcemia, renal insufficiency, etc. These complications not only affect patients' quality of life but may also shorten survival. However, with aggressive and effective treatment, patients can prolong survival and improve quality of life.

Exact numbers about life expectancy for people with stage III multiple myeloma vary from person to person. Generally speaking, without treatment, survival is likely to be shorter. However, if standard treatment is carried out under the guidance of professional doctors, the patient's survival period can be significantly prolonged. Statistics show that the remission rate after initial treatment can reach 70%~80%, 5 the annual survival rate 34.7%,< /span>10The annual survival rate is 17.4%, and the median survival time is 72 months. These data suggest that, even in stage III, it is possible for patients to achieve relatively long survival with aggressive treatment.

In addition, factors such as patient differences, age, physical condition, and psychological state will also have an impact on survival. Patients who are younger and in good health tend to respond better to treatment and may survive longer. Therefore, for patients with stage III multiple myeloma, it is crucial to actively cooperate with treatment and maintain a good mentality and living habits.

Overall, survival for patients with stage III multiple myeloma varies based on individual differences and treatment. With active and effective treatment, patients can extend their survival and improve their quality of life. When facing this challenge, patients should maintain a positive and optimistic attitude and work closely with their doctors to develop the best treatment plan.

(Common multiple myeloma treatment drugs include: melphalan, melphalan, bortezomib, ixazomib, etc. For specific drug details, please see the website homepage or click for consultation.)